Efficacy and safety of ceftazidime–avibactam versus imipenem–cilastatin in the treatment of complicated urinary tract infections, including acute pyelonephritis, in hospitalized adults: results of a prospective, investigator-blinded, randomized study

References

• Foxman B. The epidemiology of urinary tract infections. Nature Rev Urol 2010;7:653-60
   PubMed Web of Science ®Google Scholar
• Bader MS, Hawboldt J, Brooks A. Management of complicated urinary tract infections in the era of antimicrobial resistance. Postgrad Med 2010;122:7-15
   PubMed Web of Science ®Google Scholar
• Neal DE Jr. Complicated urinary tract infections. Urol Clin N Am 2008;35:13-22
   PubMed Web of Science ®Google Scholar
• Kunin CM. Urinary-catheter-associated infections in the elderly. Int J Antimicrob Agents 2006;28(Suppl 1):S78-81
   PubMedGoogle Scholar
• Ben-Ami R, Rodríguz-Baño J, Arslan H, et al. A multinational survey of risk factors for infection with extended-spectrum β-lactamase-producing Enterobacteriaceae in nonhospitalized patients. Clin Infect Dis 2009;49:682-90
   PubMed Web of Science ®Google Scholar
• Pitout JD. Infections with extended-spectrum beta-lactamase-producing enterobacteriaceae: changing epidemiology and drug treatment choices. Drugs 2010;70:313-33
   PubMed Web of Science ®Google Scholar
• Nordmann P, Cuzon G, Naas T. The real threat of Klebsiella pneumoniae carbapenemase producing bacteria. Lancet Infect Dis 2009;9:228-36
   PubMed Web of Science ®Google Scholar
• Kanj SS, Kanafani ZA. Current concepts in antimicrobial therapy against resistant Gram-negative organisms: Extended-spectrum β-lactamase-producing Enterobacteriaceae, carbapenem-resistant Enterobacteriaceae, and multidrug-resistant Pseudomonas aeruginosa. Mayo Clin Proc 2011;86:250-9
   PubMed Web of Science ®Google Scholar
• Pfeifer Y, Cullik A, Witte W. Resistance to cephalosporins and carbapenems in Gram-negative bacterial pathogens. Int J Med Microbiol 2010;300:371-9
   PubMed Web of Science ®Google Scholar
• Patel G, Bonomo RA. Status report on carbapenemases: challenge and prospects. Expert Rev Anti Infect Ther 2011;9:555-70
   PubMed Web of Science ®Google Scholar
• Arnold RS, Thom KA, Sharma S, et al. Emergence of Klebsiella pneumonia carbapenemase-producing bacteria. South Med J 2011;104:40-5
   PubMed Web of Science ®Google Scholar
• Goulenok TM, Majed K, Monchi M. Role and impact of carbapenem in nosocomial infections. Recent Pat Antiinfect Drug Discov 2011;6:45-53
   PubMedGoogle Scholar
• Livermore DM, Mushtaq S, Warner M, et al. NXL104 combinations versus Enterobacteriaceae with CTX-M extended-spectrum beta-lactamases and carbapenemases. J Antimicrob Chemother 2008;62:1053-6
   PubMed Web of Science ®Google Scholar
• Endimiani A, Choudhary Y, Bonomo RA. In vitro activity of NXL104 in combination with beta-lactams against Klebsiella pneumoniae isolates producing KPC carbapenemases. Antimicrob Agents Chemother 2009;53:3599-601
   PubMed Web of Science ®Google Scholar
• Stachyra T, Levasseur P, Péchereau MC, et al. In vitro activity of the beta-lactamase inhibitor NXL104 against KPC-2 carbapenemase and Enterobacteriaceae expressing KPC carbapenemases. J Antimicrob Chemother 2009;64:326-9
   PubMed Web of Science ®Google Scholar
• Lagacé-Weins PR, Tailor F, Simner P, et al. Activity of NXL104 in combination with beta-lactams against genetically characterized Escherichia coli and Klebsiella pneumoniae isolates producing class A extended-spectrum beta-lactamases and class C beta-lactamases. Antimicrob Agents Chemother 2011;55:2434-7
   PubMed Web of Science ®Google Scholar
• Livermore DM, Mushtaq S, Warner M, et al. Activities of NXL104 combinations with ceftazidime and aztreonam against carbapenemase-producing Enterobacteriaceae. Antimicrob Agents Chemother 2011;55:390-4
   PubMed Web of Science ®Google Scholar
• United States Department of Health and Human Services, Food and Drug Administration. Guidance for Industry. Complicated Urinary Tract Infections and Pyelonephritis – Developing Antimicrobial Drugs for Treatment. Draft Guidance, 1998. Available at: www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm064980.htm [Last accessed 3 January 2012]
   Google Scholar
• Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing; Twentieth informational supplement. M100-S20, Wayne, PA, USA, 2010
   Google Scholar
• Wagenlehner FME, Cek M, Naber KG, et al. Epidemiology, treatment and prevention of healthcare-associated urinary tract infections. World J Urol 2012;30:59-67
   PubMed Web of Science ®Google Scholar
• Naber KG, Llorens L, Kaniga K, et al. Intravenous doripenem at 500 milligrams versus levofloxacin at 250 milligrams, with an option to switch to oral therapy, for treatment of complicated lower urinary tract infection and pyelonephritis. Antimicrob Agents Chemother 2009;53:3782-92
   PubMed Web of Science ®Google Scholar
• Kamidono S, Arakawa S, Hirose T, et al. [Double-blind, controlled study to evaluate safety and efficacy of doripenem and meropenem in patients with complicated urinary tract infection.] [Article in Japanese.] Jpn J Chemother 2005;53(Suppl 1):244-59
   Google Scholar
• Nowé P. Piperacillin/tazobactam in complicated urinary tract infections. Intensive Care Med 1994;20(Suppl 3):S39-42
   PubMed Web of Science ®Google Scholar
• Sifuentes-Osornio J, Jakob E, Clara L, et al. Piperacillin/tazobactam in the treatment of hospitalized patients with urinary tract infections: an open non-comparative and multicentered trial. J Chemother 1996;8:122-9
   PubMed Web of Science ®Google Scholar
• Buckley MM, Brogden RN, Barradell LB, et al. Imipenem/cilastatin. A reappraisal of its antibacterial activity, pharmacokinetic properties and therapeutic efficacy. Drugs 1992;44:408-44
   PubMed Web of Science ®Google Scholar
• Derevianko II, Nefedova LA, Lavrinova LN. [Effectiveness of imipenem/cilastatin (Tienam, MSD) in treating complicated infections in urology.] [Russian.] Urologiia 2002 May–June;(3):21-5
   Google Scholar
• Keynan S, Hooper NM, Felici A, et al. The renal membrane dipeptidase (dehydropepetidase I) inhibitor, cilastatin, inhibits the bacterial metallo-β-lactamase enzyme CphA. Antimicrob Agents Chemother 1995;39:1629-31
   PubMed Web of Science ®Google Scholar